Document Detail


Development of a disposable magnetically levitated centrifugal blood pump (MedTech Dispo) intended for bridge-to-bridge applications--two-week in vivo evaluation.
MedLine Citation:
PMID:  20928936     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Last year, we reported in vitro pump performance, low hemolytic characteristics, and initial in vivo evaluation of a disposable, magnetically levitated centrifugal blood pump, MedTech Dispo. As the first phase of the two-stage in vivo studies, in this study we have carried out a 2-week in vivo evaluation in calves. Male Holstein calves with body weight of 62.4–92.2 kg were used. Under general anesthesia, a left heart bypass with a MedTech Dispo pump was instituted between the left atrium and the descending aorta via left thoracotomy. Blood-contacting surface of the pump was coated with a 2-methacryloyloxyethyl phosphorylcholine polymer. Post-operatively, with activated clotting time controlled at 180–220 s using heparin and bypass flow rate maintained at 50 mL/kg/min, plasma-free hemoglobin (Hb), coagulation, and major organ functions were analyzed for evaluation of biocompatibility. The animals were electively sacrificed at the completion of the 2-week study to evaluate presence of thrombus inside the pump,together with an examination of major organs. To date, we have done 13 MedTech Dispo implantations, of which three went successfully for a 2-week duration. In these three cases, the pump produced a fairly constant flow of 50 mL/Kg/min. Neurological disorders and any symptoms of thromboembolism were not seen. Levels of plasma-free Hb were maintained very low. Major organ functions remained within normal ranges. Autopsy results revealed no thrombus formation inside the pump. In the last six cases, calves suffered from severe pneumonia and they were excluded from the analysis. The MedTech Dispo pump demonstrated sufficient pump performance and biocompatibility to meet requirements for 1-week circulatory support. The second phase (2-month in vivo study) is under way to prove the safety and efficacy of MedTech Dispo for 1-month applications.
Authors:
Eiki Nagaoka; Takeshi Someya; Takashi Kitao; Taro Kimura; Tomohiro Ushiyama; Wataru Hijikata; Tadahiko Shinshi; Hirokuni Arai; Setsuo Takatani
Related Documents :
3355386 - Effect of right ventricular bypass peak flow-rate on intrapulmonary shunt ratio.
16625656 - Effect of design on the performance of a dry powder inhaler using computational fluid d...
3752726 - Assessment of intra-aortic balloon pumping by ocular pneumoplethysmography.
18204326 - Fibrinolytic activation during long-term support with the heartmate ii left ventricular...
7942376 - Distribution of feline blood types detected in the copenhagen area of denmark.
3061726 - Automation in blood banking and hemotherapy.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Artificial organs     Volume:  34     ISSN:  1525-1594     ISO Abbreviation:  Artif Organs     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-06     Completed Date:  2011-01-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802778     Medline TA:  Artif Organs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  778-83     Citation Subset:  IM    
Copyright Information:
© 2010, Copyright the Authors. Artificial Organs © 2010, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
Affiliation:
Department of Cardiothoracic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cattle
Coated Materials, Biocompatible
Disposable Equipment*
Heart-Assist Devices* / adverse effects
Hemoglobins / metabolism
Magnetics*
Male
Materials Testing
Methacrylates
Models, Animal
Phosphorylcholine / analogs & derivatives
Prosthesis Design
Thrombosis / blood,  etiology,  prevention & control
Time Factors
Chemical
Reg. No./Substance:
0/Coated Materials, Biocompatible; 0/Hemoglobins; 0/Methacrylates; 107-73-3/Phosphorylcholine; 67881-98-5/2-methacryloyloxyethyl phosphorylcholine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Managing social difficulties: roles and responsibilities of patients and staff.
Next Document:  Hedgehog pathway activation in chronic myeloid leukemia.